Wright Medical Group (NASDAQ:WMGI) Receives a Higher Rating From Guggenheim. What’s The Reasoning Behind This Move?

June 13, 2018 - By Ash

Wright Medical Group N.V. (NASDAQ:WMGI) Logo

Wright Medical Group (NASDAQ:WMGI) Stock Upgrade

In analysts report revealed on Wednesday morning, Guggenheim announced that they have decided to upgrade shares of Wright Medical Group (NASDAQ:WMGI) stock from a Neutral to a Buy.

Wright Medical Group N.V. (NASDAQ:WMGI) Ratings Coverage

Among 6 analysts covering Wright Medical Group (NASDAQ:WMGI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Wright Medical Group has $32.0 highest and $25 lowest target. $27.33’s average target is 6.01% above currents $25.78 stock price. Wright Medical Group had 14 analyst reports since January 2, 2018 according to SRatingsIntel. The rating was maintained by Piper Jaffray with “Buy” on Wednesday, February 28. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, March 12. The company was maintained on Wednesday, February 28 by Barclays Capital. As per Wednesday, January 17, the company rating was maintained by RBC Capital Markets. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, January 8. Robert W. Baird maintained the shares of WMGI in report on Wednesday, February 28 with “Buy” rating. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, April 30. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, May 21. The rating was maintained by BMO Capital Markets with “Outperform” on Wednesday, February 28. The firm earned “Buy” rating on Tuesday, January 2 by Piper Jaffray.

The stock increased 4.46% or $1.1 during the last trading session, reaching $25.78. About 3.10 million shares traded or 220.94% up from the average. Wright Medical Group N.V. (NASDAQ:WMGI) has declined 9.52% since June 13, 2017 and is downtrending. It has underperformed by 22.09% the S&P500.

Analysts await Wright Medical Group N.V. (NASDAQ:WMGI) to report earnings on August, 1. They expect $-0.07 EPS, 0.00 % or $0.00 from last year’s $-0.07 per share. After $-0.01 actual EPS reported by Wright Medical Group N.V. for the previous quarter, Wall Street now forecasts 600.00 % negative EPS growth.

Wright Medical Group N.V., a medical device company, designs, makes, markets, and sells extremities and biologics products.in the United States, Europe, the Middle East, Africa, and internationally. The company has market cap of $2.73 billion. The firm offers joint implants and bone fixation devices for the shoulder, elbow, wrist, hand, foot, and ankle; and biologics products that are used for supporting the treatment of damaged or diseased bones, tendons, and soft tissues, as well as to stimulate bone growth. It currently has negative earnings. It also provides sports medicines and other products to mechanically repair tissue-to-tissue or tissue-to-bone injuries.

More notable recent Wright Medical Group N.V. (NASDAQ:WMGI) news were published by: Seekingalpha.com which released: “FDA OKs Wright Medical’s Augment bone graft” on June 13, 2018, also Globenewswire.com with their article: “Wright Medical Group NV to Present at Jefferies Global Healthcare Conference” published on May 17, 2018, Investingnews.com published: “Wright Medical Announces FDA Premarket Approval for AUGMENT Injectable Bone Graft” on June 13, 2018. More interesting news about Wright Medical Group N.V. (NASDAQ:WMGI) were released by: Streetinsider.com and their article: “Wright Medical Group (WMGI) Reports FDA Premarket Approval for AUGMENT Injectable Bone Graft” published on June 13, 2018 as well as Nasdaq.com‘s news article titled: “Report: Exploring Fundamental Drivers Behind Syros Pharmaceuticals, J & J Snack Foods, Wright Medical Group NV …” with publication date: May 21, 2018.

Wright Medical Group N.V. (NASDAQ:WMGI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: